Journal article icon

Journal article

Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.

Abstract:

Tumour necrosis factor alpha (TNFalpha) is likely to be involved in the pathogenesis of Wegener's granulomatosis. This paper reviews published clinical trials of the anti-TNFalpha agents etanercept and infliximab with regard to their efficacy and safety in the treatment of Wegener's granulomatosis. On the basis of the high rate of adverse events, particularly an increased incidence of cancers, the use of etanercept in the management of Wegener's granulomatosis is not justified. However, the p...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1136/ard.2005.042416

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, NDORMS
Role:
Author
Journal:
Annals of the rheumatic diseases
Volume:
64 Suppl 4
Issue:
SUPPL. 4
Pages:
iv31-iv36
Publication date:
2005-11-05
DOI:
EISSN:
1468-2060
ISSN:
0003-4967
URN:
uuid:b78f66c3-0004-4b89-9c41-018838f807ac
Source identifiers:
108298
Local pid:
pubs:108298

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP